Keqian Biology(SH:688526)2021-04-26 16:00Financial Performance - Operating revenue for the period was CNY 318,927,420.10, representing an increase of 82.31% year-on-year[11] - Net profit attributable to shareholders was CNY 168,950,625.50, up 82.47% from the same period last year[11] - Basic earnings per share increased by 38.46% to CNY 0.36[11] - Total operating revenue for Q1 2021 was RMB 318,927,420.10, a 82.2% increase from RMB 174,932,713.89 in Q1 2020[44] - Net profit for Q1 2021 reached RMB 168,950,625.50, compared to RMB 92,592,590.72 in Q1 2020, representing an increase of 82.4%[47] - Operating profit for Q1 2021 was RMB 194,451,741.36, up from RMB 108,505,803.66 in Q1 2020, marking a growth of 79.3%[47] Cash Flow - Net cash flow from operating activities was CNY 249,064,874.40, a significant increase of 141.39% compared to the previous year[11] - Cash flow from operating activities for the first quarter of 2021 was RMB 249,064,874.40, up from RMB 103,178,083.85 in the first quarter of 2020, indicating a significant improvement[55] - The total cash inflow from operating activities was RMB 414,865,153.69 in the first quarter of 2021, compared to RMB 171,250,176.11 in the same period of 2020, reflecting strong operational performance[55] Assets and Liabilities - Total assets at the end of the reporting period reached CNY 3,359,818,537.41, an increase of 8.00% compared to the end of the previous year[11] - The company's accounts receivable increased by 37.90% to approximately ¥210.83 million as of March 31, 2021, compared to ¥152.89 million at the end of 2020, mainly due to increased sales volume[22] - The company's inventory rose by 30.32% to approximately ¥92.62 million as of March 31, 2021, up from ¥71.07 million at the end of 2020, attributed to increased stocking in response to higher sales[22] - The company's total liabilities reached approximately $482.35 million, up from $402.40 million, indicating an increase of about 19.9%[35] - Current liabilities rose to approximately $433.38 million, up from $354.18 million, indicating a growth of about 22.3%[35] Research and Development - R&D investment accounted for 6.60% of operating revenue, a slight decrease of 0.08 percentage points from the previous year[11] - Research and development expenses for Q1 2021 were approximately ¥21.04 million, an increase of 79.98% compared to ¥11.69 million in Q1 2020, reflecting the company's commitment to enhancing R&D efforts[26] - Research and development expenses for Q1 2021 were RMB 21,038,754.76, compared to RMB 11,689,573.82 in Q1 2020, showing an increase of 79.5%[44] Shareholder Information - The total number of shareholders at the end of the reporting period was 9,008[17] - The largest shareholder, Wuhan Huazhong Agricultural University Asset Management Company, held 16.78% of the shares[17] Investment and Financial Activities - The company reported a significant increase in investment income of 658.41% to approximately ¥1.22 million in Q1 2021, compared to ¥0.16 million in Q1 2020, resulting from the maturity of structured deposits[26] - The company's financial expenses increased by 130.40% to approximately -¥13.08 million in Q1 2021, compared to -¥5.68 million in Q1 2020, primarily due to increased interest on deposits[26] - The net cash flow from investing activities was negative at RMB -5,345,327.22 for the first quarter of 2021, compared to RMB -15,306,082.93 in the same period of 2020, showing improved investment efficiency[55] Comprehensive Income - The company’s total comprehensive income for the first quarter of 2021 was RMB 168,328,095.29, reflecting a strong financial position[51]